Q2 2024 EPS Estimates for HilleVax, Inc. (NASDAQ:HLVX) Lifted by Leerink Partnrs

HilleVax, Inc. (NASDAQ:HLVX) – Stock analysts at Leerink Partnrs lifted their Q2 2024 earnings per share estimates for shares of HilleVax in a research report issued on Tuesday, July 9th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of ($0.82) for the quarter, up from their prior forecast of ($0.89). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for HilleVax’s current full-year earnings is ($2.54) per share. Leerink Partnrs also issued estimates for HilleVax’s Q3 2024 earnings at ($0.42) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($2.46) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.21) EPS and FY2027 earnings at ($1.42) EPS.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.13).

Other research analysts have also issued research reports about the stock. Guggenheim lowered shares of HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. SVB Leerink downgraded shares of HilleVax from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $28.00 to $2.00 in a research note on Tuesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a research report on Monday, July 8th. Stifel Nicolaus lowered HilleVax from a “buy” rating to a “hold” rating and decreased their target price for the company from $34.00 to $3.00 in a report on Tuesday. Finally, HC Wainwright reissued a “neutral” rating and set a $2.00 target price (down from $28.00) on shares of HilleVax in a research note on Tuesday. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.20.

HilleVax Stock Performance

Shares of HilleVax stock opened at $1.75 on Thursday. The stock has a market capitalization of $87.01 million, a price-to-earnings ratio of -0.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.92 and a quick ratio of 10.92. The business has a 50-day moving average of $12.56 and a 200 day moving average of $14.41. HilleVax has a 12 month low of $1.55 and a 12 month high of $20.22.

Institutional Investors Weigh In On HilleVax

Institutional investors and hedge funds have recently bought and sold shares of the stock. Catalys Pacific LLC acquired a new stake in shares of HilleVax in the 4th quarter valued at about $21,009,000. Franklin Resources Inc. increased its holdings in shares of HilleVax by 4.1% in the 4th quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock valued at $29,635,000 after acquiring an additional 71,938 shares during the period. abrdn plc purchased a new stake in HilleVax in the 4th quarter valued at $433,000. Tidal Investments LLC acquired a new stake in HilleVax during the 1st quarter worth $207,000. Finally, SG Americas Securities LLC purchased a new position in HilleVax during the 4th quarter worth $139,000. 86.42% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Aditya Kohli sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total transaction of $88,380.00. Following the sale, the director now owns 764,878 shares of the company’s stock, valued at approximately $11,266,652.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 12,898 shares of company stock valued at $193,766 in the last ninety days. Insiders own 71.10% of the company’s stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.